April 2, 2013
Dainippon Sumitomo Pharma (DSP) announced on March 29 that the company signed on March 28 a license agreement with US-based Edison Pharmaceuticals for the research, development, and commercialization of the mitochondrial disease treatments EPI-743 and EPI-589 in Japan. The two...read more